168 related articles for article (PubMed ID: 28228561)
1. To PLEX or not to PLEX in natalizumab-associated PML.
Tyler KL; Vollmer TL
Neurology; 2017 Mar; 88(12):1108-1109. PubMed ID: 28228561
[No Abstract] [Full Text] [Related]
2. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
[TBL] [Abstract][Full Text] [Related]
3. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
4. Do we have enough evidence for recommending therapeutic plasma exchange for patients with natalizumab-associated progressive multifocal leukoencephalopathy?
Pham HP; Raju D; Schwartz J
J Clin Apher; 2018 Jun; 33(3):452-453. PubMed ID: 29446163
[No Abstract] [Full Text] [Related]
5. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
Pitarokoili K; Gold R
Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
[No Abstract] [Full Text] [Related]
6. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab-induced PML: can the beast be tamed?
Hohlfeld R
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1065. PubMed ID: 23475818
[No Abstract] [Full Text] [Related]
9. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
[TBL] [Abstract][Full Text] [Related]
10. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
Dahlhaus S; Hoepner R; Chan A; Kleiter I; Adams O; Lukas C; Hellwig K; Gold R
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1068-74. PubMed ID: 23606731
[TBL] [Abstract][Full Text] [Related]
11. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
12. Progressive Multifocal Leukoencephalopathy associated to treatment with natalizumab in Mexican patient Multiple Sclerosis. Case report, analysis and update.
Quiñones-Aguilar S; Sauri-Suárez S; Alcaraz-Estrada SL; García S
Neuro Endocrinol Lett; 2019 Dec; 40(5):222-226. PubMed ID: 32112546
[TBL] [Abstract][Full Text] [Related]
13. [A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab].
Simaniv TO; Ivanova MV; Bryukhov VV; Zakharova MN
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):98-106. PubMed ID: 31156248
[TBL] [Abstract][Full Text] [Related]
14. Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical?
Arnaud FX; Hissene A; Métivier D; Dutasta F; Berets O; N'guema B; A'teriitéhau C; Baccialone J; Potet J
J Neuroradiol; 2012 Oct; 39(4):267-70. PubMed ID: 22341620
[TBL] [Abstract][Full Text] [Related]
15. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.
Khatri BO; Man S; Giovannoni G; Koo AP; Lee JC; Tucky B; Lynn F; Jurgensen S; Woodworth J; Goelz S; Duda PW; Panzara MA; Ransohoff RM; Fox RJ
Neurology; 2009 Feb; 72(5):402-9. PubMed ID: 19188571
[TBL] [Abstract][Full Text] [Related]
16. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
17. Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.
Wüthrich C; Popescu BF; Gheuens S; Marvi M; Ziman R; Denq SP; Tham M; Norton E; Parisi JE; Dang X; Lucchinetti CF; Koralnik IJ
J Neuropathol Exp Neurol; 2013 Nov; 72(11):1043-51. PubMed ID: 24128680
[TBL] [Abstract][Full Text] [Related]
18. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
19. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
Rossi F; Newsome SD; Viscidi R
Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
[TBL] [Abstract][Full Text] [Related]
20. Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
Tan LA; Lopes DK
J Clin Neurosci; 2015 Oct; 22(10):1669-71. PubMed ID: 26115897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
